Cannabidiol (CBD) is a phytocannabinoid with multiple pharmacological effects and several potential therapeutic properties. Its low oral bioavailability, however, can limit its clinical use. Preliminary results indicate that fluorination of the CBD molecule increases its pharmacological potency. The findings of this study show that HUF-101 produced antinociceptive effects at lower doses than CBD, indicating that the addition of fluoride improved its pharmacological profile. Furthermore, some of the antinociceptive effects of CBD and HUF-101 effects seem to involve the activation of CB1 and CB2 receptors.
Possible to probable range of efficacy of cannabis for treatment of Pain (Acute) according to the results found in this study.
HUF-101 (3, 10, and 30 mg/kg), a fluorinated CBD analogue. CBD (10, 30, and 90 mg/kg) and WIN55,212-2 (1, 3, and 5 mg/kg).